How to Prescribe Nexium IV (Esomeprazole Intravenous)
For high-risk peptic ulcer bleeding after successful endoscopic hemostasis, administer esomeprazole 80 mg IV bolus over 30 minutes, followed by continuous infusion of 8 mg/hour for 72 hours. 1, 2
Dosing Regimens by Indication
Peptic Ulcer Bleeding (High-Risk Stigmata)
Initial Phase (72 hours):
- Loading dose: 80 mg IV bolus over 30 minutes
- Maintenance: 8 mg/hour continuous IV infusion for 71.5 hours
- This regimen is indicated after successful endoscopic hemostasis in patients with Forrest Ia, Ib, IIa, or IIb lesions 1, 2
Post-Infusion Phase:
Clinical Evidence: This high-dose IV regimen reduced clinically significant rebleeding at 72 hours from 10.3% to 5.9% (p=0.026), with sustained benefits through 30 days 2. The regimen also reduced endoscopic re-treatment needs (6.4% vs 11.6%, p=0.012) 2.
Alternative Administration Methods
3-Minute IV Injection:
- Esomeprazole 40 mg can be administered as a 3-minute IV injection instead of 30-minute infusion
- Both methods produce equivalent acid suppression (time with pH >4 was 0.99 on day 1 and 1.03 on day 10 for injection vs infusion) 3
- Use this method when rapid administration is needed in acute settings
Important: The 3-minute injection provides the same therapeutic effect as the 30-minute infusion, offering flexibility in clinical practice 3.
Preparation and Reconstitution
While the FDA label 1 provides detailed instructions for oral formulations, IV esomeprazole requires specific reconstitution:
- Follow institutional protocols for IV preparation
- Administer through appropriate IV access
- Can be given as bolus or continuous infusion depending on clinical scenario
Key Clinical Considerations
Timing Relative to Endoscopy:
- Initiate IV esomeprazole immediately after successful endoscopic hemostasis
- Do not delay administration waiting for oral intake capability
- Pre-endoscopy PPI administration may reduce stigmata of bleeding but does not replace urgent endoscopy 4
Patient Selection:
- Reserve high-dose IV regimen for patients with high-risk stigmata (active bleeding or visible vessel)
- For adherent clots, consider endoscopic therapy or PPI therapy alone 5
- Multiethnic efficacy has been demonstrated, including Asian and Western populations 2, 6
Transition Strategy:
- After 72-hour IV infusion, switch to oral esomeprazole 40 mg twice daily for 11 days (days 3-14), then 40 mg once daily for additional 2 weeks in high-risk patients 5
- This twice-daily regimen after high-dose IV therapy reduced rebleeding (RR 0.37,95% CI 0.19-0.73) 5
Safety Profile
Common Adverse Events:
- Infusion-site reactions occur in 4.3% of patients (mild, transient, do not require discontinuation) 7
- Overall adverse event frequency similar to placebo (39.2% vs 41.9%) 7
- Gastrointestinal disorders most common (12.3%) 7
Mortality:
- All-cause mortality was 0.8% with esomeprazole vs 2.1% with placebo (not statistically significant) 7
- Only one death occurred during the 72-hour IV treatment phase 7
Common Pitfalls to Avoid
Underdosing: Do not use standard PPI doses (20-40 mg once or twice daily) for acute peptic ulcer bleeding with high-risk stigmata—the evidence supports the specific high-dose regimen (80 mg bolus + 8 mg/hour infusion) 2
Premature oral transition: Complete the full 72-hour IV infusion before switching to oral therapy, as this duration is evidence-based 2
Inadequate post-infusion therapy: Continue oral esomeprazole for full 27-30 days, using twice-daily dosing for the first 2 weeks in high-risk patients 5
Ignoring H. pylori: Test and treat H. pylori infection after acute bleeding episode resolves. For eradication, use esomeprazole 40 mg once daily with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 10 days 1, 8